SUPN
Supernus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$43.53
−1.00%Margins
Gross margin
88.1%
EBITDA margin
-1.9%
EBIT margin
-13.5%
Net margin
-13.2%
FCF margin
2.3%
-10.7%
Return on equity
-7.7%
Return on assets
-10.4%
Return on invested capital
0.57x
Asset turnover
$19.9M
Cash from operations
$6.40
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026